PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 526 shares of the business's stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $28.37, for a total transaction of $14,922.62. Following the sale, the executive vice president now owns 59,988 shares in the company, valued at $1,701,859.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
PTC Therapeutics Stock Down 4.1 %
Shares of PTCT opened at $27.82 on Friday. The stock has a 50 day moving average price of $28.05 and a 200 day moving average price of $25.42. PTC Therapeutics, Inc. has a 52-week low of $17.53 and a 52-week high of $59.84.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.53). The company had revenue of $307.06 million during the quarter, compared to analysts' expectations of $315.90 million. Research analysts anticipate that PTC Therapeutics, Inc. will post -5.95 EPS for the current year.
Wall Street Analyst Weigh In
The system that called 2023’s top 7 stocks is at it again…
From WealthPress | Ad
Look 2023 kind of sucked from a trading standpoint…
Despite the market finishing 24% higher….
Just seven stocks did all of the work…
Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped…
According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Just follow this link here!
A number of brokerages have issued reports on PTCT. Wells Fargo & Company began coverage on shares of PTC Therapeutics in a research note on Friday, December 8th. They set an "overweight" rating and a $37.00 price target on the stock. TD Cowen cut their target price on shares of PTC Therapeutics from $32.00 to $30.00 and set a "market perform" rating on the stock in a research note on Friday, March 1st. Morgan Stanley lowered shares of PTC Therapeutics from an "equal weight" rating to an "underweight" rating and set a $28.00 target price on the stock. in a research note on Tuesday, December 19th. Royal Bank of Canada upped their target price on shares of PTC Therapeutics from $22.00 to $28.00 and gave the stock a "sector perform" rating in a research note on Friday, March 1st. Finally, Jefferies Financial Group upped their target price on shares of PTC Therapeutics from $33.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, March 20th. Five research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $33.53.
Check Out Our Latest Report on PTC Therapeutics
Hedge Funds Weigh In On PTC Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of PTC Therapeutics by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 8,800,843 shares of the biopharmaceutical company's stock valued at $242,551,000 after acquiring an additional 855,354 shares during the period. Wellington Management Group LLP boosted its holdings in shares of PTC Therapeutics by 4.0% in the fourth quarter. Wellington Management Group LLP now owns 9,816,603 shares of the biopharmaceutical company's stock valued at $270,546,000 after acquiring an additional 380,415 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of PTC Therapeutics by 54.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 526,494 shares of the biopharmaceutical company's stock valued at $14,510,000 after acquiring an additional 186,608 shares during the period. American International Group Inc. boosted its holdings in shares of PTC Therapeutics by 1.3% in the fourth quarter. American International Group Inc. now owns 35,815 shares of the biopharmaceutical company's stock valued at $987,000 after acquiring an additional 462 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of PTC Therapeutics by 5.3% in the fourth quarter. Public Employees Retirement System of Ohio now owns 29,846 shares of the biopharmaceutical company's stock valued at $823,000 after acquiring an additional 1,500 shares during the period.
About PTC Therapeutics
(
Get Free Report)
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
